Related references
Note: Only part of the references are listed.Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
Geoffrey A. Bartholomeusz et al.
BLOOD (2007)
Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor
Yasuo Morishima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy
Martin Weisser et al.
LEUKEMIA & LYMPHOMA (2007)
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias
Ellen Weisberg et al.
BLOOD (2007)
Resistance to targeted therapy in chronic myelogenous leukemia
Andreas Hochhaus et al.
SEMINARS IN HEMATOLOGY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Shinya Kimura et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2006)
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience
H Kantarjian et al.
CANCER (2005)
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes et al.
CLINICAL CANCER RESEARCH (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Effects of imatinib on normal hematopoiesis and immune activation
S Appel et al.
STEM CELLS (2005)
Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice
E Gluckman et al.
EXPERIMENTAL HEMATOLOGY (2004)
To the editor: Discontinuation of imatinib therapy after achieving a molecular response
J Cortes et al.
BLOOD (2004)
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia
V Rocha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis
G Michel et al.
BLOOD (2003)
Wash-out of DMSO does not improve the speed of engraftment of cord blood transplantation: follow-up of 46 adult patients with units shipped from a single cord blood bank
T Nagamura-Inoue et al.
TRANSFUSION (2003)
Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis
LP Koh et al.
BONE MARROW TRANSPLANTATION (2003)
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
HM Kantarjian et al.
BLOOD (2003)
Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults
JN Barker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia:: results in nine patients from a single institution
GF Sanz et al.
BONE MARROW TRANSPLANTATION (2001)
Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats
RA de Weger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
Share Paper
